Mirum Pharmaceuticals, Inc.(MIRM)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

MIRM Mirum Pharmaceuticals, Inc.

交易中 06-01 14:03:26 EDT

95.85

-5.65

-5.56%

最高100.27	最低93.68	成交量26.69万
今开100.00	昨收101.50	日振幅6.49%
总市值58.45亿	流通市值50.87亿	总股本6,098万
成交额2,564万	换手率0.50%	流通股本5,307万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"MIRM","market":"US","secType":"STK","nameCN":"Mirum Pharmaceuticals, Inc.","latestPrice":95.8525,"timestamp":1780337002097,"preClose":101.5,"halted":0,"volume":266926,"delay":0,"changeRate":-0.05564039408866989,"floatShares":53070600,"shares":60977800,"eps":-13.6,"marketStatus":"交易中","change":-5.6475,"latestTime":"06-01 14:03:26 EDT","open":100,"high":100.27,"low":93.68,"amount":25635669.133360002,"amplitude":0.064926,"askPrice":96.01,"askSize":5,"bidPrice":95.69,"bidSize":307,"shortable":3,"etf":0,"ttmEps":-13.6,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1780344000000},"marketStatusCode":2,"adr":0,"listingDate":1563422400000,"exchange":"NASDAQ","adjPreClose":101.5,"preHourTrading":{"tag":"盘前","latestPrice":100.5,"preClose":101.5,"latestTime":"09:29 EDT","volume":707,"amount":71909.865062,"timestamp":1780320599926,"change":-1,"changeRate":-0.009852,"amplitude":0.016552},"postHourTrading":{"tag":"盘后","latestPrice":101.5,"preClose":101.5,"latestTime":"19:55 EDT","volume":137529,"amount":13959036.1613,"timestamp":1780098941695,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.50891,"impliedVol":0.8309,"impliedVolPercentile":0.9442},"requestUrl":"/m/hq/s/MIRM","defaultTab":"news","newsList":[{"id":"1105034196","title":"Mirum Pharmaceuticals在欧洲肝病研究学会国际肝病大会上公布罕见肝病项目新数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1105034196","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1105034196?lang=zh_cn&edition=full","pubTime":"2026-05-31 00:00","pubTimestamp":1780156813,"startTime":"0","endTime":"0","summary":"Mirum Pharmaceuticals, Inc. (MIRM) 宣布，其针对罕见肝病的研究项目所取得的最新数据，已在2026年欧洲肝病研究学会（EASL）国际肝病大会上正式公布。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MIRM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104283418","title":"异动解读 | 药物研究进展获分析师看好，Mirum Pharmaceuticals盘中大涨5.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=1104283418","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1104283418?lang=zh_cn&edition=full","pubTime":"2026-05-13 21:54","pubTimestamp":1778680466,"startTime":"0","endTime":"0","summary":"Mirum Pharmaceuticals, Inc.今日盘中股价大涨5.26%，引起了市场的广泛关注。消息面上，该公司近期宣布其用于治疗罕见肝病的药物volixibat在一项中期研究中达到了主要目标，这一积极的临床进展增强了市场对公司研发管线的信心。与此同时，公司也完成了总额6亿美元的可转换优先票据的定价工作，并计划将部分募集资金用于赎回2029年到期的部分票据，以优化其债务结构。这一系列的公司动态共同构成了推动股价上涨的重要因素。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["MIRM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177923329","title":"Mirum Pharmaceuticals完成6亿美元可转换优先票据定价 并部分赎回2029年到期票据","url":"https://stock-news.laohu8.com/highlight/detail?id=1177923329","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177923329?lang=zh_cn&edition=full","pubTime":"2026-05-13 11:56","pubTimestamp":1778644574,"startTime":"0","endTime":"0","summary":"Mirum Pharmaceuticals宣布完成总额6亿美元的可转换优先票据发行的定价工作。与此同时，公司计划将此次发行所得款项的一部分，用于赎回其2029年到期的部分可转换票据，以实现债务结构的优化。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIRM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193143463","title":"Mirum制药Volixibat安全性特征与IBAT抑制作用一致 主要表现为胃肠道事件及肝酶升高","url":"https://stock-news.laohu8.com/highlight/detail?id=1193143463","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1193143463?lang=zh_cn&edition=full","pubTime":"2026-05-04 20:10","pubTimestamp":1777896611,"startTime":"0","endTime":"0","summary":"Mirum Pharmaceuticals公司公布的研究数据显示，其核心候选药物volixibat的安全性特征与回肠胆汁酸转运蛋白（IBAT）抑制机制高度吻合。临床观察发现，该药物引发的不良反应主要集中于胃肠道范畴，同时伴有肝脏生化参数的可逆性升高。\n值得注意的是，这类安全性表现完全符合IBAT抑制剂类药物已知的作用机理预期。研究人员强调，胃肠道反应与肝酶指标变化均属可控范围，为后续临床开发提供了重要安全性依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MIRM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186217776","title":"Mirum Pharmaceuticals预计2027年第一季度公布Volixibat治疗PBC的Vantage二期B阶段研究顶线数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1186217776","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1186217776?lang=zh_cn&edition=full","pubTime":"2026-05-04 20:05","pubTimestamp":1777896314,"startTime":"0","endTime":"0","summary":"Mirum Pharmaceuticals宣布，针对原发性胆汁性胆管炎（PBC）的Volixibat药物Vantage二期B阶段临床研究，预计将于2027年第一季度获得顶线数据结果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIRM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156368450","title":"Mirum制药公司计划2026年夏季与FDA召开Volixibat治疗PSC的新药申请前会议 拟于2026年下半年提交NDA","url":"https://stock-news.laohu8.com/highlight/detail?id=1156368450","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1156368450?lang=zh_cn&edition=full","pubTime":"2026-05-04 20:03","pubTimestamp":1777896229,"startTime":"0","endTime":"0","summary":"Mirum Pharmaceuticals, Inc.宣布，针对Volixibat用于原发性硬化性胆管炎治疗的研发取得重要进展。公司已安排于2026年夏季与美国食品药品监督管理局举行新药申请前会议，此举标志着该药物研发进入关键阶段。根据公司规划，在完成Pre-NDA会议并获取监管机构反馈后，Mirum拟于2026年下半年正式提交Volixibat治疗PSC的新药申请。此次披露的监管时间节点，不仅体现了公司对研发进程的精准把控，也预示着该药物向商业化迈出了实质性步伐。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIRM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101296019","title":"Mirum制药Volixibt实现瘙痒评分降低2.72分 较安慰剂组优势达1.64分（P<0.0001）","url":"https://stock-news.laohu8.com/highlight/detail?id=1101296019","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1101296019?lang=zh_cn&edition=full","pubTime":"2026-05-04 20:03","pubTimestamp":1777896199,"startTime":"0","endTime":"0","summary":"Mirum Pharmaceuticals, Inc.旗下药物Volixibat在最新临床试验中展现出显著疗效。数据显示，该药物可使患者瘙痒评分平均降低2.72分，相较于安慰剂组取得的1.08分改善，治疗效果优势达到1.64分。这一差异具有高度统计学意义（P<0.0001），表明Volixibat在缓解瘙痒症状方面具有显著临床价值。\n研究结果进一步验证了Volixibat作为新型治疗方案的潜力。药物通过特异性作用机制靶向疾病根源，为相关患者群体提供了新的治疗选择。此次数据公布为Mirum Pharmaceuticals, Inc.后续的监管申报和商业化进程奠定了重要基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIRM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197260913","title":"Mirum Pharmaceuticals宣布Volixibat治疗原发性硬化性胆管炎的Vistas研究达到主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1197260913","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1197260913?lang=zh_cn&edition=full","pubTime":"2026-05-04 20:02","pubTimestamp":1777896160,"startTime":"0","endTime":"0","summary":"Mirum Pharmaceuticals宣布，其药物Volixibat在针对原发性硬化性胆管炎（PSC）患者开展的Vistas研究中，成功达到了预设的主要疗效终点。该重要里程碑标志着公司在肝胆疾病治疗领域的研发取得关键进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIRM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189451881","title":"Mirum制药宣布Brelovitug治疗慢性丁型肝炎的Azure-1研究2B阶段达成主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1189451881","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1189451881?lang=zh_cn&edition=full","pubTime":"2026-04-27 20:14","pubTimestamp":1777292063,"startTime":"0","endTime":"0","summary":"Mirum Pharmaceuticals, Inc. (MIRM) 今日宣布，其针对慢性丁型肝炎病毒（HDV）的创新药物Brelovitug在Azure-1临床研究的2B阶段取得了重大进展，成功达到了预设的主要疗效终点。\n这一关键性成果标志着Brelovitug在治疗这一难治性肝脏疾病的发展道路上迈出了坚实的一步。丁型肝炎是一种严重的病毒性肝炎，目前全球范围内的治疗选择极为有限。Azure-1研究2B阶段的成功，为饱受该疾病困扰的患者带来了新的希望。\n公司表示，将基于此次获得的积极数据，与监管机构进行沟通，并积极推进该药物的后续临床开发计划。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MIRM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121811592","title":"Mirum制药完成Livmarli®治疗罕见胆汁淤积性肝病三期扩展研究患者招募","url":"https://stock-news.laohu8.com/highlight/detail?id=1121811592","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1121811592?lang=zh_cn&edition=full","pubTime":"2026-03-16 20:40","pubTimestamp":1773664821,"startTime":"0","endTime":"0","summary":"Mirum Pharmaceuticals, Inc.宣布已完成Livmarli®（maralixibat）针对其他罕见胆汁淤积性肝病的三期扩展研究（EXPAND）患者招募工作。\n该研究的顶线数据预计将于2026年第四季度公布。这项进展标志着Mirum在拓展罕见肝病治疗领域迈出关键一步，为患者带来新的希望。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MIRM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124176149","title":"Mirum制药公司：Azure-1与Azure-4预计将于2027年在美国提交BLA申请并上市","url":"https://stock-news.laohu8.com/highlight/detail?id=1124176149","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1124176149?lang=zh_cn&edition=full","pubTime":"2026-03-05 21:04","pubTimestamp":1772715899,"startTime":"0","endTime":"0","summary":"Mirum Pharmaceuticals, Inc. 旗下药物Azure-1和Azure-4有望在2027年向美国监管机构提交生物制剂许可申请（BLA），并计划同期实现商业化上市。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MIRM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176149465","title":"Mirum Pharmaceuticals公布Brelovitug治疗慢性丁型肝炎病毒Azure临床项目最新进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1176149465","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1176149465?lang=zh_cn&edition=full","pubTime":"2026-03-05 21:02","pubTimestamp":1772715730,"startTime":"0","endTime":"0","summary":"Mirum Pharmaceuticals, Inc.近日针对其候选药物Brelovitug在慢性丁型肝炎病毒感染治疗中的Azure临床研究项目，发布了最新动态更新。此次更新涵盖了该临床试验项目的关键进展与后续规划。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MIRM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177135125","title":"异动解读 | Evercore上调目标价并看好药物潜力，Mirum Pharmaceuticals盘中大涨5.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=1177135125","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177135125?lang=zh_cn&edition=full","pubTime":"2026-03-05 03:09","pubTimestamp":1772651362,"startTime":"0","endTime":"0","summary":"Mirum Pharmaceuticals, Inc.  今日盘中股价大幅上涨5.07%，引起了市场的广泛关注。消息面上，知名投行Evercore ISI将Mirum Pharmaceuticals的目标价从101美元大幅上调至126美元，并重申了“跑赢大盘”的评级。具体来看，Mirum预计将在2026年第二季度获得实验性肝病药物volixibat的中期数据以及D型肝炎候选药物brelovitug的中晚期数据。券商预计，用于治疗原发性硬化性胆管炎的volixibat在全球的未调整峰值销售额可达12亿美元，这进一步增强了市场对公司未来增长潜力的信心。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["MIRM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101130484","title":"Mirum制药公司提交SEC文件：股东拟发售最高896万股普通股","url":"https://stock-news.laohu8.com/highlight/detail?id=1101130484","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1101130484?lang=zh_cn&edition=full","pubTime":"2026-02-26 06:20","pubTimestamp":1772058025,"startTime":"0","endTime":"0","summary":"根据最新提交给美国证券交易委员会（SEC）的文件显示，Mirum Pharmaceuticals, Inc.已正式登记由售股股东发起的普通股公开发行计划。此次发售规模最高可达896万股，所有股份均由现有股东提供，公司本身不会从此次发售中获得任何收益。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIRM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610100930","title":"Mirum Pharmaceuticals, Inc.跌0.54% 股价跌破100美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2610100930","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610100930?lang=zh_cn&edition=full","pubTime":"2026-02-10 22:32","pubTimestamp":1770733977,"startTime":"0","endTime":"0","summary":"北京时间2026年02月10日22时32分，Mirum Pharmaceuticals, Inc.股票出现波动，股价快速跳水0.54%。Mirum Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为0.02%。其相关个股中，Quince Therapeutics, Inc.、Abpro Holdings, Inc、Evommune, Inc.涨幅较大，Abpro Holdings, Inc、Phio Pharmaceuticals Corp.、Quince Therapeutics, Inc.较为活跃，换手率分别为991.87%、627.18%、448.48%，振幅较大的相关个股有Quince Therapeutics, Inc.、Abpro Holdings, Inc、Evommune, Inc.，振幅分别为52.69%、15.79%、12.95%。Mirum Pharmaceuticals, Inc.公司简介：Mirum Pharmaceuticals Inc 是一家生物制药公司， 专注于识别、收购、开发和商业化用于使人衰弱的罕见疾病和孤儿疾病的新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260210223258a4940720&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260210223258a4940720&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["MIRM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115897314","title":"Mirum Pharmaceuticals宣布加拿大卫生部批准Livmarli®用于治疗进行性家族性肝内胆汁淤积症（PFIC）患者的胆汁淤积性瘙痒","url":"https://stock-news.laohu8.com/highlight/detail?id=1115897314","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115897314?lang=zh_cn&edition=full","pubTime":"2026-02-05 21:00","pubTimestamp":1770296417,"startTime":"0","endTime":"0","summary":"Mirum Pharmaceuticals, Inc. 近日宣布，加拿大卫生部已正式批准其药物Livmarli®用于治疗进行性家族性肝内胆汁淤积症（PFIC）患者的胆汁淤积性瘙痒。这一授权标志着该药物在加拿大市场的准入，为患有此种罕见肝病的患者提供了新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIRM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156667431","title":"Mirum制药完成收购Bluejay Therapeutics 强化罕见病领域全球领导地位","url":"https://stock-news.laohu8.com/highlight/detail?id=1156667431","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1156667431?lang=zh_cn&edition=full","pubTime":"2026-01-26 21:01","pubTimestamp":1769432497,"startTime":"0","endTime":"0","summary":"Mirum Pharmaceuticals, Inc.近日宣布已完成对Bluejay Therapeutics公司的全面收购。这一战略举措显著拓展了Mirum在罕见病治疗领域的全球布局，进一步巩固了其行业领先地位。通过本次收购，Mirum获得了Bluejay Therapeutics在罕见肝病领域的创新研发管线及专业技术。这将为Mirum现有产品组合注入新的活力，增强其解决复杂罕见疾病的能力。此次交易不仅拓展了Mirum的全球业务版图，更彰显了其长期致力于罕见病治疗领域的坚定承诺。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIRM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603688965","title":"Mirum Pharmaceuticals, Inc.盘中异动 股价大跌5.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603688965","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603688965?lang=zh_cn&edition=full","pubTime":"2026-01-12 22:37","pubTimestamp":1768228674,"startTime":"0","endTime":"0","summary":"北京时间2026年01月12日22时37分，Mirum Pharmaceuticals, Inc.股票出现异动，股价急速跳水5.28%。Mirum Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为1.44%。Mirum Pharmaceuticals, Inc.公司简介：Mirum Pharmaceuticals Inc 是一家生物制药公司， 专注于识别、收购、开发和商业化用于使人衰弱的罕见疾病和孤儿疾病的新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260112223754a7120935&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260112223754a7120935&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","MIRM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185803639","title":"Mirum制药公司2025年初步净产品销售额约5.2亿美元 超预期指引上限","url":"https://stock-news.laohu8.com/highlight/detail?id=1185803639","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1185803639?lang=zh_cn&edition=full","pubTime":"2026-01-12 21:33","pubTimestamp":1768224780,"startTime":"0","endTime":"0","summary":"Mirum Pharmaceuticals, Inc. 近日公布的2025年初步业绩数据显示，其净产品销售额达到约5.2亿美元，这一数字显著超越了公司此前设定的业绩指引上限。\n这一亮眼成绩凸显了公司核心产品的市场竞争力与商业化进展。销售额的超预期表现，不仅反映了患者需求的持续增长，也印证了公司销售策略的有效执行。在医药行业面临多重挑战的背景下，Mirum能够实现如此强劲的销售增长，为其未来的发展奠定了坚实的基础。\n市场分析人士认为，这一积极的初步数据可能会增强投资者信心，并对公司未来的股价表现产生积极影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MIRM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116304908","title":"Mirum制药公司：伏利昔巴特治疗原发性硬化性胆管炎Vistas研究顶线数据预计2026年第二季度公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1116304908","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1116304908?lang=zh_cn&edition=full","pubTime":"2026-01-12 21:32","pubTimestamp":1768224761,"startTime":"0","endTime":"0","summary":"Mirum Pharmaceuticals, Inc.宣布，其针对原发性硬化性胆管炎（PSC）开发的伏利昔巴特（volixibat）Vistas研究，预计将于2026年第二季度获得顶线数据。该研究旨在评估伏利昔巴特治疗这一慢性胆汁淤积性肝病的疗效与安全性。\n此次数据公布将成为评估该疗法潜力的关键节点，备受市场关注。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MIRM"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.mirumpharma.com","stockEarnings":[{"period":"1week","weight":0.0292},{"period":"1month","weight":0.0775},{"period":"3month","weight":0.0998},{"period":"6month","weight":0.3895},{"period":"1year","weight":1.3068},{"period":"ytd","weight":0.285}],"compareEarnings":[{"period":"1week","weight":0.0145},{"period":"1month","weight":0.0631},{"period":"3month","weight":0.1028},{"period":"6month","weight":0.107},{"period":"1year","weight":0.2821},{"period":"ytd","weight":0.1093}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Mirum Pharmaceuticals, Inc.于2018年5月2日在特拉华州注册成立。该公司是一家生物制药公司，专注于识别、收购、开发和商业化用于使人衰弱的罕见和孤儿疾病的新疗法。","yearOnYearQuotes":[{"month":1,"riseRate":0.714286,"avgChangeRate":0.06611},{"month":2,"riseRate":0.714286,"avgChangeRate":0.037723},{"month":3,"riseRate":0.428571,"avgChangeRate":-0.043043},{"month":4,"riseRate":0.571429,"avgChangeRate":0.058316},{"month":5,"riseRate":0.285714,"avgChangeRate":-0.02467},{"month":6,"riseRate":0.666667,"avgChangeRate":0.097654},{"month":7,"riseRate":0.666667,"avgChangeRate":0.076249},{"month":8,"riseRate":0.714286,"avgChangeRate":0.107618},{"month":9,"riseRate":0.285714,"avgChangeRate":-0.04362},{"month":10,"riseRate":0.142857,"avgChangeRate":-0.10761},{"month":11,"riseRate":0.714286,"avgChangeRate":0.084664},{"month":12,"riseRate":0.571429,"avgChangeRate":0.315468}],"exchange":"NASDAQ","name":"Mirum Pharmaceuticals, Inc.","nameEN":"Mirum Pharmaceuticals, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.3","shortVersion":"4.42.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Mirum Pharmaceuticals, Inc.(MIRM)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Mirum Pharmaceuticals, Inc.(MIRM)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Mirum Pharmaceuticals, Inc.,MIRM,Mirum Pharmaceuticals, Inc.股票,Mirum Pharmaceuticals, Inc.股票老虎,Mirum Pharmaceuticals, Inc.股票老虎国际,Mirum Pharmaceuticals, Inc.行情,Mirum Pharmaceuticals, Inc.股票行情,Mirum Pharmaceuticals, Inc.股价,Mirum Pharmaceuticals, Inc.股市,Mirum Pharmaceuticals, Inc.股票价格,Mirum Pharmaceuticals, Inc.股票交易,Mirum Pharmaceuticals, Inc.股票购买,Mirum Pharmaceuticals, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Mirum Pharmaceuticals, Inc.(MIRM)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Mirum Pharmaceuticals, Inc.(MIRM)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}